EMV
data caveat$142MCF+
Emvision Medical Devices
Neurology
Strokefinder portable MRI device for rapid stroke triage at point of care
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$18.4M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$142M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
93M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther26 May 2026
Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
EMVision completed a successful aeromedical feasibility and usability study of its First Responder Brain Scanner with the Royal Flying Doctor Service, demonstrating the device can be effectively deployed and operated in real-world pre-hospital environments. The study showed positive operator feedback, acceptable scan quality unaffected by flight conditions, and 92% of participants felt calm during scanning. The company received the final $400,000 non-dilutive milestone payment from the Australian Stroke Alliance Project Agreement.
3M Price
EMV.ASX$1.520-8.4% 3M
Low $1.520High $1.955
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNet Buy
Buys1+1 vs prior
Sells0
Buy Value$18k
Catalysts (4)· 2 upcoming · 2 past
SpeculativeremoveMed31 Jan 2027(2× delayed)
Expectedarrow_upwardHigh31 Jan 2027
expand_more2 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· 1 catalyst re-guided (2×)· of 4 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_down
Trial data readout — Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection — Upcoming — delayed 2× from original date
arrow_drop_up
Cash-flow positive — 1/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
Completed catalysts
✓EMVision to Receive $1.17M IGP Grant Instalment— EMVision has achieved progress milestones under its Australian Government IGP grant, triggering a $1.17 million instalment payment expected this month. The company has received $1 million to date of a $5 million total non-dilutive grant awarded in June 2025, with $2.83 million remaining available to support First Responder brain scanner commercialisation.
On time
✓Aeromedical Study De-Risks Rural & Remote Stroke Use Cases— EMVision completed a successful aeromedical feasibility and usability study of its First Responder Brain Scanner with the Royal Flying Doctor Service, demonstrating the device can be effectively deployed and operated in real-world pre-hospital environments. The study showed positive operator feedback, acceptable scan quality unaffected by flight conditions, and 92% of participants felt calm during scanning. The company received the final $400,000 non-dilutive milestone payment from the Australia
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 441d
Brain Scan
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
Stroke · Hemorrhagic Stroke
22 Years+
Primary endpoint Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
ENROL300
no manual snapshots — enter via record_enrollment.py
Announcements(13)
article
OtherPSauto_awesome
Aeromedical Study De-Risks Rural & Remote Stroke Use Cases26 May 2026
expand_more324KB
article
OtherPSauto_awesome
EMVision to Receive $1.17M IGP Grant Instalment24 May 2026
expand_more183KB
article
OtherPSauto_awesome
emu Pivotal Trial Expansion Adds Acute Ischaemia Detection10 May 2026
expand_more346KB